On July 31, the FDA approved prophylactic labeling revisions.

On July 31, the FDA approved remedy labeling revisions for nelfinavir mesylate tablets and oral grind (Viracept; Pfizer, Inc) to warn of drug interactions with phosphodiesterase type 5 (PDE5) inhibitors.
Concomitant use of protease inhibitors, such as nelfinavir, can significantly difference of order of magnitude PDE5 inhibitor concentrations and the risk for adverse events such as hypotension, visual changes, and priapism.
This is a part of article On July 31, the FDA approved prophylactic labeling revisions. Taken from "Aygestin Norethindrone Acetate" Information Blog